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Zellweger syndrome is the archetypical peroxisome biogenesis disorder and is characterized by defective
import of proteins into the peroxisome, leading to peroxisomal metabolic dysfunction and widespread tissue
pathology. In humans, mutations in the PEX13 gene, which encodes a peroxisomal membrane protein necessary
for peroxisomal protein import, can lead to a Zellweger phenotype. To develop mouse models for this disorder,
we have generated a targeted mouse with a loxP-modified Pex13 gene to enable conditional Cre recombinase-
mediated inactivation of Pex13. In the studies reported here, we crossed these mice with transgenic mice that
express Cre recombinase in all cells to generate progeny with ubiquitous disruption of Pex13. The mutant pups
exhibited many of the clinical features of Zellweger syndrome patients, including intrauterine growth retar-
dation, severe hypotonia, failure to feed, and neonatal death. These animals lacked morphologically intact
peroxisomes and showed deficient import of matrix proteins containing either type 1 or type 2 targeting signals.
Biochemical analyses of tissue and cultured skin fibroblasts from these animals indicated severe impairment
of peroxisomal fatty acid oxidation and plasmalogen synthesis. The brains of these animals showed disordered
lamination in the cerebral cortex, consistent with a neuronal migration defect. Thus, Pex13/ mice reproduce
many of the features of Zellweger syndrome and PEX13 deficiency in humans.
The peroxisome biogenesis disorders (PBDs) are neurode-
generative disorders that result from defective biogenesis of
the peroxisome, a ubiquitous cellular organelle (17). Peroxi-
somes are required for a number of essential metabolic func-
tions, including the -oxidation of very long chain fatty acids
(VLCFA), oxidation of phytanic acid, and syntheses of bile
acids and ether-phospholipids (28). PBDs are autosomal re-
cessive diseases that arise from mutations in PEX genes that
encode proteins, called peroxins, required for the normal bio-
genesis of the peroxisome (8, 16). Mutations in peroxins either
directly disrupt the apparatus required for posttranslational
import into the peroxisome of matrix proteins containing ei-
ther a PTS1 or PTS2 peroxisomal targeting signal or indirectly
prevent matrix protein import by disrupting peroxisomal mem-
brane formation (35). The PBDs are thus characterized by the
absence, or deficiency, of normal peroxisomes and loss of this
organelle’s usual complement of proteins and metabolic path-
ways. Of the PBDs, Zellweger syndrome (ZS), neonatal adre-
noleukodystrophy (NALD), and infantile Refsum’s disease
(IRD) represent a clinical continuum, called the Zellweger
spectrum, with ZS the most severe and IRD towards the milder
end of the phenotypic spectrum.
Animal models provide a valuable resource for investigating
the pathogenesis of human diseases. Three mouse models for
ZS have been developed through targeted disruption of the
Pex2 (12), Pex5 (1), and Pex11 (22) genes. All three knockout
animals exhibit many of the organ abnormalities typical of ZS,
including hypotonia and impaired neocortex neuronal migra-
tion and maturation. Unfortunately, Pex5/, Pex2/, and
Pex11/ pups die at or shortly after birth, limiting their
usefulness as models of postnatal disease pathogenesis. In ad-
dition, they are not suitable for delineating tissue-specific pa-
thology. To circumvent these obstacles and allow a more wide-
spread and detailed analysis of the cellular and tissue changes
that occur in the PBDs, we have initiated the development of
a conditional Pex gene mouse model using the Cre/loxP recom-
bination system of gene manipulation in embryonic stem cells
(21, 29).
PEX13 is a peroxisomal integral membrane protein with an
essential role in both PTS1 and PTS2 protein import. In Sac-
charomyces cerevisiae, the cytoplasmic SH3 domain of PEX13
binds PEX5, the PTS1 receptor (9, 10, 15). Deletion of PEX13
results in a marked reduction in the level of PEX5 associated
with the peroxisomal membrane at steady state and loss of
both PTS1 and PTS2 protein import (15). In humans, muta-
tions in PEX13 lead to a Zellweger spectrum disease pheno-
type and define complementation group 13 of the PBDs. Two
mutations in this gene have been reported, a missense muta-
tion in a mildly affected NALD patient (23, 39) and a nonsense
mutation in a ZS patient (39).
On the basis of this established function of PEX13 in hu-
mans, we propose that targeted disruption of the mouse Pex13
gene would provide a good model of the peroxisome protein
import defects and pathogenesis of the PBDs. Here we report
on a mouse mutant in which Pex13 has been ubiquitously
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disrupted using the Cre/loxP system. Pex13-deficient mice re-
produce many of the features of ZS patients, including intra-
uterine growth retardation, hypotonia, abnormal peroxisomal
metabolism, and neonatal lethality. This disease phenotype is
associated with defective peroxisome biogenesis, confirming
the essential role of Pex13 in the molecular mechanisms of
peroxisomal matrix protein import in mammals.
MATERIALS AND METHODS
Animal use. All research described involving animals has been approved by the
ethics committees of Griffith University or the Queensland Institute of Medical
Research and has complied with the guidelines and policies of the National
Health and Medical Council of Australia and the Office of the Gene Technology
Regulator.
Generation of Pex13 knockout mice using the Cre-loxP system. We have
previously reported on the genomic organization of the murine Pex13 gene (3)
and the generation of mice with a loxP-flanked Pex13 allele (4). The loxP-flanked
Pex13 allele incorporates loxP sites (recognized by Cre recombinase) that flank
exon 2. The loxP-flanked sequence also incorporates a neomycin resistance gene
flanked by FRT sites (4), providing a mechanism for separately removing this
cassette by crossing animals with transgenic mice expressing Flp recombinase.
Animals heterozygous for a Cre recombinase-mediated disrupted Pex13 allele
were obtained by crossing females heterozygous for the loxP-flanked allele with
a male Cre-deleter transgenic mouse (X-linked transgene) that expresses Cre
recombinase ubiquitously from the two-cell stage onwards under the control of
a human cytomegalovirus minimal promoter (37). Female progeny positive for
the disrupted Pex13 allele (4) were backcrossed to a male C57BL6/J mouse to
generate male and female animals that were heterozygous for the disrupted
Pex13 allele and also Cre recombinase negative. Pex13 homozygous knockout
animals were generated by crossing progeny heterozygous for the disrupted
Pex13 allele. PCR analysis of tail biopsy genomic DNA was undertaken using
primers P1 (5-ATGGCTCCCAAGTTAGTTCTG-3) and P2 (5-TCTGTTTC
CCTCCCACCTC-3) to amplify a 492-bp fragment specific to the wild-type
allele, primers P3 (5-TGGCTCCCAAGTTAGTTCTGTC-3) and P4 (5-CCT
CTCTATTTGTTGCTTACCCC-3) to amplify a 385-bp fragment specific to the
disrupted Pex13 allele (see Fig. 1A), and primers Cre-F (5-CACCCTGTTAC
GTATAGC-3) and Cre-R (5-CTAATCGCCATCTTCCAG-3) to detect the
Cre recombinase gene.
Northern analysis, RT-PCR, and in vitro transcription and translation. RNA
from mouse tissue was prepared using the RNeasy kit (Qiagen, Clifton Hill, Aus-
tralia) according to the manufacturer’s instructions. Northern blot analysis of Pex13
expression using tissue RNA was performed as previously described (3). For reverse
transcription (RT), RNA was first treated for 1 h at 37°C with 3 U of RQ1 DNase
(Promega, Madison, Wis.), followed by phenol-chloroform extraction and ethanol
precipitation. RT reactions were performed using 2 g of DNase-treated RNA, 0.5
M T30MN oligonucleotide and 200 U of SuperScript III reverse transcriptase,
according to the manufacturer’s instructions (Invitrogen, Melbourne, Australia). RT
product was PCR amplified using primers that flank the Pex13 open reading frame.
The product was gel extracted and sequenced directly using an Applied Biosystems
377 sequencer and BigDye terminator cycle sequencing (Applied Biosystems, Foster
City, Calif.). Alternatively, the product was first cloned into pGEM-Teasy vector
(Promega) and subclones were sequenced. In vitro transcription and translation of
[35S]methionine-labeled protein from the Pex13/ RT-PCR product, subcloned
into pSP64poly(A) (Promega), was performed and analyzed as previously described
(3).
Plasmid constructs. JB221, a pcDNA3-based plasmid encoding the full-length
mouse Pex13 protein with a C-terminal myc epitope tag, has been described
previously (3). The pPTS2-EGFP plasmid, encoding the minimal rat PTS2 signal
fused to the amino-terminal end of enhanced green fluorescent protein (EGFP),
was created by blunt cloning of the 0.9-kb BglI-NotI fragment from the PTSwt-
GFP plasmid (7) into EcoRV-digested pcDNA3 vector (Invitrogen).
Cell culture and fluorescence microscopy. Primary mouse skin fibroblast cul-
tures were produced from skin biopsies of newborn mice 0.5 day postpartum
(dpp). Cells were cultured in a mixture of Dulbecco’s modified Eagle medium
and Ham F-12 medium supplemented with 10% fetal bovine serum, 100 g of
penicillin per ml, and 100 U of streptomycin per ml (both antibiotics from
Invitrogen, Melbourne, Australia). Cell transfection, using Lipofectamine 2000
(Invitrogen) and 3 g of relevant plasmid, and indirect immunofluorescence
were performed as previously described for human skin fibroblasts (24, 25). The
anti-SKL and anti-rat PMP70 antibodies (Zymed Laboratories Inc., San Fran-
cisco, Calif.) were used at dilutions of 1/200 and 1/500, respectively.
Liver fractionation and Western blot analysis. Livers were removed from
newborn mouse pups (0.5 dpp), weighed, frozen in liquid nitrogen, and stored at
80°C. Liver portions (approximately 20 mg) were subsequently thawed on ice
and homogenized in 200 l of cold 0.25 M sucrose–0.1% ethanol containing
protease inhibitors (50 g of leupeptin per ml, 10 g of pepstatin per ml, 10 g
of chymostatin per ml, and 200 M phenylmethylsulfonyl fluoride) (SEPI buffer)
using one stroke of a Potter-Elvehjem homogenizer rotating at 1,000 rpm. A
sample of homogenate was added to 0.5 volume of 3 sodium dodecyl sulfate
(SDS) sample buffer (3 SDS sample buffer is 30% glycerol, 6% SDS, 15%
-mercaptoethanol, 0.2% bromophenol blue, and 187.5 mM Tris-HCl buffer [pH
6.8]) and immediately heated for 5 min in a boiling water bath prior to SDS-
polyacrylamide gel electrophoresis. Western blotting was performed as previ-
ously described, using antibodies to mouse liver catalase, peroxisomal bifunc-
tional protein, and PMP70 (5), or mouse Pex13 (3). The antibody to mouse
Pex13 was raised against recombinant maltose-binding protein fused to the
region of Pex13 encompassing the SH3 domain to the C terminus (see Fig. 1B).
The remaining liver homogenate was centrifuged using a Sorvall RC-5B centri-
fuge for 10 min at 1,000  g to sediment nuclei and unbroken cells. The
supernatant from this step was centrifuged for 10 min at 16,000  g to produce
an organelle pellet and postorganellar supernatant. These fractions were sus-
pended to equivalent volumes in SEPI buffer and assayed for catalase activity or
mixed with SDS sample buffer as described above for SDS-polyacrylamide gel
electrophoresis.
Biochemical analyses. Catalase activity in mouse liver fractions was assayed by
a kinetic spectrophotometric procedure (6). The identities and levels of VLCFA
in a total lipid extract from tissue samples were determined as previously de-
scribed (33). Plasmalogens were assayed essentially as described previously (34)
FIG. 1. Targeted disruption of Pex13. (A) Schematic representation of the wild-type allele. The positions of exons 2 (E2) to 4 (E4) and the
directions and positions of genotyping PCR primers P1 to P4 are indicated. (B) Structures of proteins expressed from the wild-type (WT) Pex13
and disrupted (Pex13) alleles. The numbered boxes depict the sections of the protein encoded by the Pex13 exons and are shown to scale. The
positions of the transmembrane domain (TMD) and SH3 domain are indicated by the labeled solid lines. The dotted line represents the portion
of the protein used to raise the Pex13 antibody. Two predicted translation termination codons (**) are indicated. (C) Genotyping by PCR screening
of tissue genomic DNA. The P1/P2 primer pair generates an amplicon (490 bp) from the wild-type (WT) Pex13 allele, but not from the Pex13
allele because of the loss of the P2 primer binding sequence following Cre/loxP excision of exon 2. The P3/P4 primer pair generates an amplicon
(385 bp) from the Pex13 allele, but not from the wild-type allele because of amplicon size. L, liver; B, brain; K, kidney. (D) Northern blot analysis
of 10 g of total RNA from the liver, kidney, and brain. The blot was probed with a radioactively labeled murine Pex13 cDNA probe, stripped,
and reprobed with a labeled glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe. (E) Western blot analysis of total liver
homogenate (10 g of protein) from newborn (0.5 dpp) mice using anti-Pex13 antibody. The mobility of protein mass markers is indicated.
(F) RT-PCR of RNA from Pex13/ mouse liver. Total liver RNA was reverse transcribed and PCR amplified using primers flanking the Pex13
open reading frame. Lane M, DNA ladder with selected markers (in base pairs) indicated. (G) Sequence chromatogram of a portion of the
RT-PCR product from Pex13/ mouse liver RNA. The physiological translation start ATG (arrow) is shown. The position where exon 2 was
removed (triangle) and positions of flanking exons 1 and 3 (Ex1 and Ex3, respectively) sequences are indicated. The positions of two in-frame
translation termination codons (double underlines) are shown. (H) Appearance of newborn pups. (Left) An entire litter; (Right) one Pex13/ and
one Pex13/ animal from a second litter. Symbols: /, wild-type; /, heterozygous for the disrupted Pex13 gene; /, homozygous for the
disrupted Pex13 gene.
VOL. 23, 2003 Pex13 DEFICIENCY IN MICE 5949
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
5950 MAXWELL ET AL. MOL. CELL. BIOL.
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
but using cis-3-O-nonadec-1-enylglycerol 1,2-carbonate as the internal standard.
Measurements of the rate of phytanic acid and pristanic acid oxidation and of the
activities of alkyl-dihydroxyacetone phosphate (DHAP) synthase and DHAP
acyltransferase (DHAP-AT) in cultured skin fibroblasts were performed as pre-
viously described (32).
Histology and electron microscopy. For routine necroscopy and tissue histol-
ogy, newborn mice (0.5 dpp) were killed by carbon dioxide asphyxiation, per-
fused with Bouin’s fixative by injection into the peritoneal and thoracic cavities,
and immersed in Bouin’s fixative for at least 7 days. Coronal brain sections, cut
at 1-mm intervals rostral to caudal, were embedded in paraffin wax, and 6-m-
thick sections were cut and stained with hematoxylin and eosin. The body was
then cut longitudinally into two equal halves and embedded in paraffin in order
to examine visceral organs. Preliminary neuropathological examination of these
mice was confined to a small number of coronal sections taken from directly
comparable levels of the brain in Pex13/ and wild-type mice. For routine
electron microscopy, tissue was removed from animals, thinly sliced, and fixed for
2 h at 4°C in 3% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.3.
Specimens were postfixed in 1% osmium tetroxide and 1% aqueous uranyl
acetate, dehydrated by immersion in a series of graded ethanol solutions, and
embedded in Spurr epoxy. Ultrathin sections (approximately 50 to 100 nm thick)
were treated with 1% aqueous uranyl acetate and Reynold’s lead citrate for
contrast and viewed using a JEOL 1200EX electron microscope operating at 80
kV. For catalase cytochemistry, liver slices were fixed for 2 h at 4°C in 0.1 M
sodium cacodylate buffer (pH 7.3) (19, 20) containing 4% formaldehyde and 1%
glutaraldehyde, incubated at 25°C for 1 h in Teorell & Stenhagen buffer (pH
10.5) (11) containing 3,3-diaminobenzidine (DAB) tetrahydrochloride (2 mg/
ml) (Sigma Chemicals, St. Louis, Mo.) and 0.05% H2O2, and washed in 0.1 M
sodium cacodylate buffer (pH 7.3). Subsequent processing was performed as
described above except that ultrathin sections were examined without further
treatment for contrast.
RESULTS
Targeted disruption of Pex13. The Cre/loxP site-specific re-
combination approach was adopted to develop mouse lines in
which the Pex13 gene could be disrupted ubiquitously or in a
cell- or developmental stage-specific manner by using appro-
priate Cre recombinase-expressing transgenic mice. Construc-
tion of the Pex13 targeting vector, generation of chimeras, and
production of animals carrying a Pex13 allele in which exon 2
is flanked by loxP sites have been described previously (4). For
generation of mice with ubiquitous disruption of Pex13, ani-
mals heterozygous for the exon 2-deleted Pex13 allele were
produced by crossing animals carrying the loxP-modified Pex13
allele with transgenic mice that express Cre recombinase ubiq-
uitously from the two-cell stage on (37). Pex13/ pups were
then generated by crossing animals heterozygous for the dis-
rupted Pex13 allele. Genotyping of pups was performed by
Southern analysis as previously described (4) (data not shown)
and then routinely by PCR analysis of genomic DNA using
primers to amplify sequence-specific fragments of the wild-
type or disrupted Pex13 alleles (Fig. 1A). Exon 2 removal
predicts a protein that lacks the essential transmembrane and
SH3 domains; the effect on Pex13 protein structure is repre-
sented diagrammatically in Fig. 1B.
PCR analyses of genomic DNA confirmed homozygous dis-
ruption of the Pex13 allele in the tail and in the other tissues
analyzed (Fig. 1C), viz., liver, brain, and kidney, consistent with
the reported ubiquitous tissue expression of the Cre recombi-
nase in the strain used. Disruption of Pex13 was demonstrated
by Northern blot analysis, which showed that the normal
mRNA transcript (approximately 2.1 kb) was not expressed in
tissues of Pex13/ animals (Fig. 1D). Western blot analysis
confirmed that the Pex13 protein (apparent molecular mass of
approximately 47 kDa) was not detectable in liver homoge-
nates of these animals (Fig. 1E). Unexpectedly, these analyses
also indicated that the disrupted allele produced a shorter,
stable mRNA transcript, whose size (approximately 1.4 kb) is
compatible with exon 2 (694-bp) deletion (Fig. 1D). The na-
ture of this transcript was investigated by RT-PCR of mRNA
from the livers of Pex13/ mice. A single product was ob-
tained (Fig. 1F). The size (approximately 520 bp) and sequence
(Fig. 1G) of the cloned cDNA product were identical to those
of the wild-type transcript, except for the absence of exon 2.
The sequence also confirmed that exon 2 removal resulted in
the introduction of immediate downstream translation termi-
nation codons, consistent with the structure and sequence of
the targeting construct (Fig. 1B).
Western blotting of liver homogenate proteins also indicated
that a low-abundance protein of approximately 26 kDa ap-
peared to segregate with the disrupted Pex13 allele (Fig. 1E).
The identity of this immunoreactive protein is not clear; the
disrupted Pex13 mRNA predicts a protein lacking the C-ter-
minal third of Pex13, the segment of the protein recognized by
the Pex13 antibody (Fig. 1B and G), and does not contain an
alternative, downstream translation start codon that could gen-
erate a protein of this molecular mass. Also, in vitro transcrip-
tion and translation from Pex13/ cDNA template produced
a single radioactive product of the predicted mass (approxi-
mately 5 kDa) (cf. Fig. 1B and G) (data not shown) and no
immunoreactive bands, as expected. We have also shown that
the 26-kDa protein is found in the supernatant (after centrif-
ugation at 100,000  g for 60 min) when the livers from
Pex13/ animals are subfractionated by differential centrifu-
gation (data not shown). These findings, together with the fact
that the Pex13/ heterozygous mice did not display a disease
phenotype (see below), suggest that this 26-kDa protein is not
acting in a dominant-negative manner and has no Pex13-re-
lated function.
FIG. 2. Pex13 deficiency disrupts protein import into peroxisomes. (A) Peroxisomal protein import in cultured skin fibroblasts from wild-type
(/) and Pex13-deficient (/) mice. PTS1 protein import assessed by indirect immunofluorescence using an anti-SKL antibody (SKL panels),
PTS2 protein import assessed by GFP autofluorescence in cells transfected with a plasmid that expresses a PTS2-EGFP fusion protein (GFP
panels), and peroxisomal membranes detected by indirect immunofluorescence using an antibody to the peroxisomal integral membrane protein
PMP70 (PMP panels) are shown. Note that GFP fluorescence and PMP70 immunofluorescence are from the same cell in each case. Bars, 10 m.
(B) Transfection of Pex13/ cells with a plasmid that expresses wild-type, myc-tagged Pex13 rescues import of PTS1 and PTS2-EGFP protein
import. myc and SKL immunofluorescence in the same cell (top) and GFP fluorescence and SKL immunofluorescence in the same cell (bottom)
are shown. (C) Western blot analysis of liver homogenates to determine the levels of the peroxisomal proteins catalase, peroxisomal bifunctional
protein (PBP), and PMP70. Actin levels indicate protein loading. Liver homogenates from wild-type (/) and heterozygous (/) and
homozygous (/) knockout animals were used. (D) Electron microscopic analysis of DAB-stained liver for detection of peroxisomes (PO) in
wild-type and Pex13/ mice. Bars, 1 m.
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Pex13-deficient mice display growth and developmental ab-
normalities. Pex13/ pups died soon after birth (6 to 12 h)
and displayed severe hypotonia and hypoactivity. The pups
showed no obvious dysmorphia but maintained a contracted
“C” posture that appeared to particularly affect the hind limbs
(Fig. 1H). The body weight of these animals was 73%  9%
(mean  standard deviation [SD]; n 	 14) of that of littermate
wild-type and heterozygote pups at the same stage (0.5 dpp),
suggesting severe intrauterine growth retardation. The pups
did not feed, as ascertained by the absence of milk in their
stomachs, and in rare cases displayed respiratory distress. In
contrast, none of the Pex13/ pups displayed a disease phe-
notype. Inheritance of the disrupted Pex13 allele was compat-
ible with normal Mendelian genetics, indicating that there was
no intrauterine loss of homozygotes.
Defective peroxisome biogenesis in Pex13-deficient mice.
The essential role of PEX13 in peroxisomal matrix protein
import in yeast (9, 10, 15), CHO cells (41), and humans (23, 39)
predicts that Pex13 deficiency in mice should lead to impaired
peroxisomal matrix protein import. To test this, skin fibroblast
cells from newborn Pex13/ pups were cultured and pro-
cessed for indirect immunofluorescence microscopy. Using an
anti-SKL antibody, which recognizes the prototypic signal re-
quired for peroxisomal import of PTS1-containing matrix pro-
teins, peroxisomes were visualized as punctate cytoplasmic flu-
orescence in cells from Pex13/ mice but were completely
absent from Pex13/ cells, where there was diffuse fluores-
cence in the cytoplasm instead (Fig. 2A). PTS2 protein import
was assessed by transfecting cells with a plasmid that encodes
GFP fused to the rat PTS2 signal. In Pex13/ cells, GFP was
detected as punctate cytoplasmic fluorescence. Double indirect
fluorescence of this same cell using an antibody to the perox-
isomal integral membrane protein PMP70 indicated peroxiso-
mal colocalization of GFP and PMP70. In Pex13/ cells, in
contrast, peroxisomal import of PTS2-EGFP was deficient, as
demonstrated by the lack of punctate GFP fluorescence, but
some peroxisomal membranes appeared to be formed nor-
mally, as indicated by PMP70-positive vesicles in the same cell.
PTS1 and PTS2 protein import defects in Pex13/ cells could
be rescued by transfection with the plasmid JB221, which ex-
presses wild-type Pex13 protein containing a C-terminal myc
tag (Fig. 2B). The results demonstrate colocalization of all
fluorescence signals in the rescued Pex13/ cells, consistent
with the detected cytoplasmic vesicles representing peroxi-
somes. These results also confirm that the molecular basis of
the biogenesis defects in these animals is Pex13 deficiency.
Peroxisome biogenesis defects in Pex13/ mice were also
assessed by determining the levels of specific peroxisomal pro-
teins in liver homogenates. Catalase is the most abundant
peroxisomal matrix protein and is imported relatively ineffi-
ciently via a nonconsensus PTS1 signal (36, 38). Total catalase
levels in the liver were relatively unchanged in Pex13-deficient
animals compared to wild-type controls (Fig. 2C). To deter-
mine the subcellular distribution of catalase in these animals,
liver homogenates were subfractionated by differential centrif-
ugation to produce an organellar pellet and a postorganellar
supernatant. The proportion of catalase in the postorganellar
supernatant, expressed as a percentage (mean  SD; n 	 3) of
the total catalase activity (organellar pellet plus postorganellar
supernatant), was 18% 1% for Pex13/ animals and 81%
6% for Pex13/ animals. These results indicate that catalase
is predominantly organelle associated in Pex13/ mice but
cytoplasmic in Pex13/ mice; the latter distribution is consis-
tent with a defect in the peroxisomal import of this protein and
the known stability of this protein in the cytoplasm. Western
blot analysis was also used to test for abundance of another
peroxisomal matrix protein, the peroxisomal bifunctional pro-
tein of the -oxidation pathway, which is also imported by the
PTS1 pathway. The amount of this protein in the liver was
reduced in Pex13/ mice, consistent with defective peroxiso-
mal import and instability or degradation of the missorted
protein. In contrast, levels of the peroxisomal membrane pro-
tein PMP70, whose peroxisomal targeting does not involve
either the PTS1 or PTS2 pathway, were not significantly af-
fected in Pex13/ mice.
To confirm that peroxisomes were depleted in the Pex13/
animals, livers were processed for DAB histochemistry and
electron microscopy to detect peroxisomal catalase. In contrast
to livers from Pex13/ mice which contained numerous DAB-
positive peroxisomes with crystalline cores, no DAB-positive
peroxisome-like structures were observed in Pex13/ animals
(Fig. 2D). When considered together, these results indicate
normal peroxisomal membrane synthesis but defective matrix
protein import in the Pex13-deficient animals.
Biochemical abnormalities of Pex13-deficient mice. ZS pa-
tients display widespread metabolic abnormalities due to the
absence of functional peroxisomes (17). To assess whether
peroxisomal metabolic function was similarly compromised in
Pex13-deficient mice, the levels of VLCFA, rates of oxidation
of branched-chain fatty acids (i.e., phytanic acid and pristanic
acid), and levels of plasmalogens and peroxisomal enzymes
required for plasmalogen synthesis were measured. VLCFA
levels, expressed as the C26:0/C22:0 ratio, were significantly el-
evated in the livers (9-fold), brains (6.5-fold), and cultured skin
fibroblasts (50-fold) of Pex13/ pups compared to wild-type
and Pex13/ animals (Fig. 3A). VLCFA levels in these tis-
sues, when expressed as the C24:0/C22:0 ratio, were up to two-
fold elevated (Fig. 3B). The rates of oxidation of the branched-
chain fatty acid phytanic acid (Fig. 3C) and its 
-oxidation
product, pristanic acid (Fig. 3D), were measured in cultured
skin fibroblasts as the production of radiolabeled CO2 and
water-soluble product from 1-14C-labeled substrate. Oxidation
rates of both these branched-chain fatty acids were decreased
by between 50- and 100-fold in Pex13/ pups compared with
wild-type and Pex13/ animals. Plasmalogen metabolism was
assessed by measuring liver and brain plasmalogen levels and
the activity in cultured skin fibroblasts of peroxisomal enzymes
required for plasmalogen synthesis. The levels of C16:0 and
C18:0 plasmalogen in the livers of Pex13
/ pups were 20-fold
and 3-fold lower, respectively, than in wild-type and Pex13/
animals (Fig. 3E). The relative levels of these plasmalogen
molecular species were even lower in the brains of Pex13/
pups (Fig. 3F). The tissue plasmalogen levels were paralleled
by marked reductions in the activities of alkyl-DHAP synthase
and DHAP-AT in fibroblasts (Fig. 3G). These results therefore
indicate severe impairment of a number of peroxisomal met-
abolic pathways in Pex13-deficient animals, consistent with a
generalized metabolic deficiency that would result from defec-
tive peroxisome biogenesis.
5952 MAXWELL ET AL. MOL. CELL. BIOL.
 o
n
 O
ctober 26, 2015 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
Tissue ultrastructural changes in Pex13-deficient mice. One
of the hallmarks of ZS is defective neuronal migration in brain.
In comparison with wild-type mice, there was reduced thick-
ness and disorganization of the neocortex in Pex13/ animals,
and much of the cortical mantle was densely populated by
neurons with small, round, hyperchromatic (pyknotic) nuclei,
often with a thin rim of amphophilic cytoplasm (Fig. 4). These
degenerate neurons also imparted increased cellularity to the
subcortical zone of radial glia, the prospective white matter,
and were present in smaller numbers in the periventricular
germinative region. These results are consistent with abnormal
neuronal migration and neuronal degeneration in Pex13-defi-
cient mice. Visceral organs were unremarkable by light micros-
copy. However, analysis of the ultrastructure of hepatocytes of
Pex13/ mice by electron microscopy revealed an abundance
of large lipid droplets (Fig. 5A), which is also a feature of ZS
patients and Pex5/ mice (1). The presence of mitochondria
with abnormal structure, in particular abnormal crista mor-
FIG. 3. Peroxisomal biochemical abnormalities in Pex13-deficient mice. VLCFA measurements in the liver, brain, and cultured skin fibroblasts
expressed as a ratio of C26:0/C22:0 (A) or C24:0/C22:0 (B) fatty acids. Oxidation of [1-
14C]phytanic acid (C) and [1-14C]pristanic acid (D) by cultured
skin fibroblasts, expressed as the production of [1-14C]CO2 and 1-
14C-water-soluble (Water-sol.) products. Levels of C16:0 and C18:0 plasmalogen
in liver (E) and brain (F). (G) Activities of peroxisomal enzymes required for plasmalogen synthesis in cultured fibroblasts. Values are the means
of three or four measurements on Pex13/ (white bars), Pex13/ (grey bars), and Pex13/ (black bars) animals. Each error bar represents one
SD.
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phology, was another distinctive feature. Typically, the appear-
ance of cristae was curvilinear and looped (Fig. 5B) or elongated
and parallel (Fig. 5C). Similar mitochondrial ultrastructural
changes have been reported for Pex5/ mice (1, 2), and mito-
chondrial abnormalities are a reported feature of ZS patients
(14). Ultrastructural analysis of kidneys revealed delayed differ-
entiation of glomeruli in Pex13/ mice, evident as reduced size
and capillary structure and paucity of podocyte foot processes
(Fig. 5D). In addition, myelin-like lipid structures were identified
in some adrenocortical cells of Pex13/ mice (data not shown).
Thus, Pex13 deficiency leads to a number of tissue ultrastructural
changes in the mouse that model many of those observed for ZS
patients.
DISCUSSION
Ubiquitous inactivation of Pex13 in mice represents the first
stage in the development of a group of PBD animal models
based on conditional inactivation of this gene using the Cre-
loxP recombination system. The Pex13/ mouse exhibits the
expected peroxisome biogenesis deficiencies, given the known
function of the PEX13 protein in peroxisomal matrix protein
import through the PTS1 and PTS2 pathways in eukaryotes. In
yeast, PEX13 is required for both PTS1 and PTS2 protein
import into the peroxisome. The role of PEX13 in PTS1 pro-
tein import involves interaction with PEX5, the PTS1 receptor.
This interaction is thought to involve a step subsequent to
binding of PTS1 cargo-laden receptor with another peroxiso-
mal membrane protein, PEX14, the primary docking protein,
and may require displacement of this cargo (42). The involve-
ment of PEX13 in PTS2 protein import reflects a primary
docking event with the PTS2 receptor, PEX7 (40). A similar
role for PEX13 in protein import in mammalian cells is indi-
cated by the disruption of both PTS1 and PTS2 protein import
in patients with PEX13 mutations (23, 39), although the mech-
anisms involved may differ slightly (31) and include a direct
interaction between cargo-laden PEX7 and PEX5 prior to
docking at the peroxisomal membrane (30).
The organelle biogenesis defects in the Pex13/ mouse,
coupled with the absence of morphologically distinguishable
FIG. 4. Pex13 deficiency leads to abnormal lamination of the cerebral cortex. (A) Matched coronal sections of wild-type (/) and Pex13-
deficient (/) mice stained with hematoxylin and eosin. Corresponding cortical layers are delimited by arrowheads. CP, cortical plate; IZ,
intermediate zone. Bars, 200 m. (B) Higher-magnification views of the cortical plate zone from the sections shown in panels A.
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peroxisomes in the liver and the presence of peroxisome ghosts
in cultured fibroblasts, are paralleled by peroxisomal metabolic
deficiency. The VLCFA levels in livers, brains, and skin fibro-
blasts are elevated and branched-chain fatty acid oxidation in
fibroblasts is severely reduced in Pex13/ mice compared to
wild-type mice. In addition, the markedly reduced levels of
plasmalogens in the brain and liver and of alkyl-DHAP syn-
thase and DHAP-AT activities in fibroblasts are indicative of a
severe impairment in plasmalogen synthesis. Defects in these
unrelated peroxisomal metabolic pathways indicate general-
ized impairment of peroxisomal metabolism in these animals,
consistent with a primary deficiency of the peroxisomal en-
zymes required for these metabolic pathways.
The clinical phenotype of Pex13/ mice indicates that these
animals are a good model of the PBDs and more specifically
for the severe ZS phenotype, as seen in the human patient
homozygous for a PEX13 nonsense mutation at W234 (39).
This finding is compatible with loss of function of a protein that
is highly conserved, in both structure and function, between
these species. In addition to the peroxisome protein import
defects and metabolic abnormalities seen in ZS patients (17,
28), the mice reproduce a subset of the pathological features of
ZS patients, including neonatal lethality, intrauterine growth
retardation, hypotonia, tissue pathology, and impaired neuro-
nal migration in the cerebral cortex. However, some ZS pa-
thology was not reproduced; these features included facial
dysmorphia, renal cysts, and specific changes to the cerebel-
lum, liver, and retina, key targets of PBD pathogenesis (27). In
this respect, the Pex13/ animals are similar to the existing
Pex2, Pex5, and Pex11 knockout animals. Many of the features
of ZS patients not modeled by the Pex13/animals may in-
volve postnatal developmental changes that are precluded by
the neonatal lethality of these animals. This limitation is also
true for the Pex2/, Pex5/, and Pex11/ pups, although
placing the Pex2 null mutation on a different genetic back-
ground has been shown to extend postnatal survival up to 18
days and allowed investigation of cerebellar changes over this
period (13). However, none of the existing knockout Pex gene
mutants is suitable for delineating the tissue-specific pathology
seen in PBD patients. In this context, the development of the
loxP-modified Pex13 mouse provides a means of circumventing
these limitations by allowing for conditional inactivation of
FIG. 5. Tissue ultrastructural changes in Pex13-deficient mice. (A) Large lipid droplet (L) in a hepatocyte. N, nucleus. Bar, 1 m. (B and C)
Hepatic mitochondria with abnormal cristae. Bars, 200 nm. (D) Section through kidney glomeruli of Pex13/ and Pex13/ mice. P, podocyte foot
processes. Bars, 1 m.
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Pex13 using transgenic animals that express Cre recombinase
in a tissue-specific or developmental stage-specific manner
(29). The presumptive central roles of the liver and brain in
PBD pathogenesis provide two immediate target tissues for
conditional inactivation of Pex13.
The molecular basis of the tissue pathogenesis of ZS and of
its milder variants, NALD and IRD, is not known. A number
of causative agents have been proposed, including elevated
VLCFA, elevated bile acid precursors, decreased plasmalogen,
and decreased docosahexaenoic acid, all of which can be re-
lated back to abnormal peroxisomal metabolism (26). Recent
investigations of the neuronal migration defects in Pex5/
animals have implicated abnormal glutamate receptor-medi-
ated calcium signaling, resulting from decreased levels of
platelet-activating factor, a plasmalogen (18). However, the
phenotype of Pex11/ animals, which includes neonatal le-
thality, hypotonia, developmental delay, abnormal neuronal
migration, and increased neuronal apoptosis, but not abnormal
peroxisomal matrix protein import or significant peroxisomal
metabolic dysfunction, appears to be incompatible with the
tenet that disease pathogenesis correlates to impaired meta-
bolic pathways involving peroxisomal matrix enzymes (22). The
explanations for these seemingly disparate findings will require
a molecular dissection of the pathogenic processes involved. In
this context, Pex13 conditional mutants represent a potentially
valuable tool and their proposed use for modeling the human
PBDs is validated by the pathogenic findings observed for the
Pex13/ mouse.
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